1. Home
  2. GPRO vs CGEN Comparison

GPRO vs CGEN Comparison

Compare GPRO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$1.46

Market Cap

282.4M

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.58

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
CGEN
Founded
2004
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.4M
143.1M
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
GPRO
CGEN
Price
$1.46
$1.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.8M
410.9K
Earning Date
02-05-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$650,751,000.00
$6,903,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.41
$231.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$1.13
52 Week High
$3.05
$2.66

Technical Indicators

Market Signals
Indicator
GPRO
CGEN
Relative Strength Index (RSI) 36.96 53.21
Support Level $1.55 $1.43
Resistance Level $1.61 $1.55
Average True Range (ATR) 0.08 0.07
MACD -0.02 0.01
Stochastic Oscillator 18.29 63.83

Price Performance

Historical Comparison
GPRO
CGEN

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: